Contributions of natural killer cells to the immune response against *Plasmodium*

Kristina S. Burrack¹, Geoffrey T. Hart² and Sara E. Hamilton³*

**Abstract**

Natural killer (NK) cells are important innate effector cells that are well described in their ability to kill virally-infected cells and tumors. However, there is increasing appreciation for the role of NK cells in the control of other pathogens, including intracellular parasites such as *Plasmodium*, the cause of malaria. NK cells may be beneficial during the early phase of *Plasmodium* infection—prior to the activation and expansion of antigen-specific T cells—through cooperation with myeloid cells to produce inflammatory cytokines like IFNγ. Recent work has defined how *Plasmodium* can activate NK cells to respond with natural cytotoxicity, and inhibit the growth of parasites via antibody-dependent cellular cytotoxicity mechanisms (ADCC). A specialized subset of adaptive NK cells that are negative for the Fc receptor γ chain have enhanced ADCC function and correlate with protection from malaria. Additionally, production of the regulatory cytokine IL-10 by NK cells prevents overt pathology and death during experimental cerebral malaria. Now that conditional NK cell mouse models have been developed, previous studies need to be reevaluated in the context of what is now known about other immune populations with similarity to NK cells (i.e., NKT cells and type I innate lymphoid cells). This brief review summarizes recent findings which support the potentially beneficial roles of NK cells during *Plasmodium* infection in mice and humans. Also highlighted are how the actions of NK cells can be explored using new experimental strategies, and the potential to harness NK cell function in vaccination regimens.

**Keywords:** Malaria, NK cells, Cytotoxicity, Cytokines

**Background**

Natural killer (NK) cells are lymphocytes of the innate immune system that participate in early defense against foreign cells and autologous cells undergoing various forms of stress, such as microbial infection or tumour transformation [1, 2]. NK cells are derived from a common lymphoid progenitor and develop primarily in the bone marrow [2]. Under homeostatic conditions, NK cells are abundant in blood, spleen, bone marrow, and liver, but they can migrate to inflamed or infected tissues in response to chemoattractants [3]. NK cells recognize Human Leukocyte Antigen (HLA) class I molecules via Killer Immunoglobulin Receptors (KIRs) that predominantly deliver signals that suppress, rather than activate NK cell function [2]. NK cell activation decisions are based on the balance of engaged inhibitory or activating receptors such as KIR, natural cytotoxicity receptors (NCRs), DNAX accessory molecule-1 (DNAM-1) and NK group 2 member D (NKG2D) [2, 4]. When inhibitory signals are reduced or absent, activating NK cell receptor ligation results in NK cell triggering and target cell death; this is referred to as natural cytotoxicity. In addition to natural cytotoxicity, NK cells can cooperate with the adaptive immune system by performing antibody-dependent cellular cytotoxicity (ADCC) upon recognition of opsonized targets via the Fc receptor—FcRγIIIa (CD16). Lastly, NK cells have the ability to induce apoptosis in target cells through Fas Ligand (FasL) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) [5, 6]. Thus, NK cells exhibit a wide variety of methods to recognize and attack cells that are a danger to the host.

NK cells also respond to cytokine signals delivered by other immune cells, namely IL-2, IL-15, IL-18, and IL-12 [7]. Exposure allows NK cells to augment immune
responses through rapid and robust production of pro-inflammatory cytokines, including interferon-gamma (IFN-γ) and tumour necrosis factor (TNF), among others. Much work has focused on this bolus of cytokine production which serves to amplify immune responses, particularly in the early hours after infection. However, NK cells may also contribute to overproduction of pro-inflammatory cytokines, which can result in immunopathology [8]. Perhaps to temper this danger, NK cells can also produce the anti-inflammatory cytokine IL-10, which limits immune responses [9–12]. Variation in the clinical symptoms associated with Plasmodium infection in humans, along with diverse characteristics in specific mouse models of infection, have made defining the protective immune response challenging. There is still not a consensus on whether NK cells are overall more harmful, helpful, or inconsequential to the immune response to Plasmodium (see review by Wolf et al. [13]). However, several recent studies have started to gain a better understanding of the mechanisms by which NK cells are activated during malaria infection and the downstream consequences of their activation. Here, findings are highlighted that relate to the potentially beneficial actions of NK cells during Plasmodium infection in mice and humans. These studies justify further evaluation of NK cells in the context of malaria disease.

**NK cells during liver stage infection**

After being bitten by a mosquito carrying Plasmodium parasites, a low number of sporozoites (on the order of 1–25) are transmitted [14]. The sporozoites travel through the blood stream to the liver and infect a small number of hepatocytes, where they replicate and differentiate into merozoites. Human trials with the RTS,S vaccine indicate that antibody against circumsporozoite protein (CSP) and CD4+ T cell responses serve as good correlates of protection [15]. CD8+ T cells are also implicated as critical effector cells in protection against pre-erythrocytic stage malaria [16, 17]. To obtain robust responses, CD8+ T cells are primed by liver-infiltrating CD11c+ cells that acquire Plasmodium antigens, traffic to the liver draining lymph nodes, and then present peptides to naive T cells [18]. NK and NKT cells are also abundant in the liver, and they are early producers of IFN-γ, which is an important effector molecule that could conceivably contribute to the activation of immune cells and indirectly lead to destruction of parasite-infected hepatocytes (Fig. 1) [19, 20].

Observational studies in humans have suggested that NK cells contribute to immunity against malaria during the liver stage of disease. However, human challenge studies are limited to showing that infection and increased protection correlated with decreased frequency and number of NK cells in the blood of subjects [21–23]. Although it is tempting to speculate that this could be due to increased trafficking to the infected liver, this is difficult to address experimentally in humans. Enhanced IFNγ production by human NK cells has been observed after RTS,S/AS01 malaria vaccination [20]. These improved responses could be due to either indirect activation of NK cells by cytokines or potentially, cognate antigen recognition. Regardless of the mechanism, NK cells in the liver might be sufficiently stimulated by vaccination to meaningfully contribute indirectly or directly to protective immune responses against Plasmodium [24].

Studies in mice have shown that NK and NKT cells both increase in number in the liver and produce increased amounts of IFNy and TNF in response to Plasmodium yoelii infection [25, 26], which could be important to dampen the growth of schizonts in the liver and amplify the early immune response. Early work investigating the protective mechanisms of radiation-attenuated sporozoites used in vivo antibody depletion to conclude that, in addition to CD8+ T cells, NK cells are required for vaccine-induced protection against P. yoelii challenge [27]. This was proposed to be the result of IL-12 activation of NK cells, which in-turn made IFNy. Additionally, using CD1d−/− mice, Miller et al. showed that NKT cells play a significant role in lowering liver parasite burden [26]. Future work can reevaluate the importance of NK cell-specific cytokine production using new, more specific technical approaches. For example, the use of Nkp46Cre mice [28] or Nkp46-CreERT2 mice [29] bred with mice containing loxP sites flanking effector molecules (IFNy, TNF) [30] would help to bolster or disprove the case that NK cell-derived cytokine production is important for Plasmodium control.
Overall, additional studies are required, in both humans and mice, to determine the exact role, if any, NK cells play in the liver during *Plasmodium* infection. The presence of additional liver populations including resident NK cells and type I innate lymphoid cells (ILC1s) further complicates assignment of individual immune cell contributions to protection from the liver stage of infection. ILC1s are CD49a+ CD49b− CXCR6+ T-bet+ Eomes− CD127lo− and are predominantly tissue-resident [31]. Conventional NK cells are largely recirculating and can be identified based on the following phenotype: CD49a− CD49b+ CXCR6− T-bet+ Eomes+ [31, 32].

To date, the contribution of NK-related cell types to protection in the liver has often relied on antibody depletion using shared markers (i.e., NK1.1). Thus, future experiments will need to precisely determine the individual impact of conventional NK cells and other similar immune cell types to pre-erythrocytic immunity.

**NK cells during blood stage infection**

Merozoites released from hepatocytes initiate the blood-stage of infection. In the bloodstream, free merozoites invade RBCs beginning a 48-h cycle of maturation followed by RBC rupture, and additional release of merozoites. Release of mature parasites from infected RBCs (iRBCs) results in symptomatic disease characterized by fever, headache, and lethargy. The most vulnerable are young children and pregnant women; severe disease takes the form of anaemia, placental disruption and miscarriage, acute respiratory distress, and cerebral manifestations [33]. With age and re-exposure, the risk of malaria goes down, and although hosts continue to carry parasite burdens, they usually do so without the associated symptoms.

**Non-severe infection - human and humanized mouse studies**

During uncomplicated malaria in *Plasmodium falciparum*-infected Kenyans, NK cell frequencies (CD56+CD3−) were reduced relative to asymptomatic and aperasitaemic people [34]. Similar results were found in a recent study of Mali subjects, but this report additionally showed that the CD56dim subset was specifically reduced during malaria episodes, whereas the CD56bright population was increased [35]. Other studies have investigated the potential protective role of NK cells during blood stage *Plasmodium* infection. In both mouse and human studies, IFNγ has been associated with control of parasitaemia, protection from malaria, and delayed reinfection [36–40]. NK cells rapidly produce IFNγ in the presence of many pathogens, including *Plasmodium* [37, 41]. However, in vitro assays indicate that IFNγ production against *Plasmodium* requires direct contact between NK cells and iRBCs and a cellular source of IL-12 and IL-18, such as monocytes or DCs [42–44].

Evidence for direct NK cell natural cytotoxicity toward *P. falciparum*-infected erythrocytes was first demonstrated by Orago and colleagues via in vitro chromium release assay [34]. This was subsequently reproduced by other studies demonstrating antibody-independent lysis of infected red blood cells by NK cells, however the percent of natural cytotoxicity responders in studies is variable [45–47]. When PBMCs from malaria-naïve individuals are incubated with iRBCs, NK cells have been shown to increase expression of the cytotoxic molecules perforin, granzyme A, and CD107a (LAMP-1) [41]. It was subsequently shown that NK cells form stable conjugates with iRBCs leading to cytoskeletal actin rearrangement [41]. A recent study showed that human NK cells can perform natural cytotoxicity in vitro, and utilized a humanized mouse model of *Plasmodium* infection (reviewed in [48]) to demonstrate that NK cells were critical for the control of parasitaemia in vivo [49]. Humanized mouse models have several limitations; in this study, the mice exhibited low parasitaemia relative to what is observed in humans, and the ligand/receptor combinations required for NK cell recognition of iRBCs have not been fully elucidated. It has been shown that antibody-mediated inhibition of NKp30 and to a lesser extent NKp46 (both natural cytotoxicity receptors) reduced lysis of iRBCs [46]. Preincubation of NK cells with a peptide from the *P. falciparum* erythrocyte membrane protein-1 (PfEMP-1) also reduced lysis, but other *Plasmodium* antigens did not have an effect [46]. These data suggest that NK cell natural cytotoxicity receptors can directly recognize *P. falciparum* PfEMP-1 proteins on iRBCs to mediate lysis.

In a separate study, Saito and colleagues found that a subset of RIFIN proteins, which are expressed on the surface of iRBCs, bind to the inhibitory receptors LILRB1 or LAIR1 on NK cells and reduced NK cell cytotoxicity [50]. A recent report suggests that microvesicles from iRBCs can fuse with NK cells in vitro and cause activation and a reduction in parasitaemia [51]. The authors found that the innate receptor MDA5, which can bind uncapped RNA, could be induced in “iRBC responsive” NK cells, and that genetic knockdown of MDA5 resulted in the loss of parasitaemia control in vitro, suggesting that parasite RNA in the microvesicles stimulated NK cells to kill iRBCs. Ye et al. also showed that stimulation of “iRBC non-responsive” NK cells with a MDA5 agonist induced activation and improved control of parasitaemia, providing evidence of a molecular basis for variation in human NK cell responses to malaria [51]. However, the proportion of people with “responder” vs. “non-responder” NK cell phenotypes was not reported.
A recent study showed that NK cell-mediated cytotoxicity required antibody; that is, NK cells killed iRBCs via ADCC and inhibited the growth of Plasmodium in vitro [52] (Fig. 2a). In this study the destruction of iRBCs was highly specific, as uninfected RBCs in the same culture were not lysed, and killing was dependent on Fc receptors. It was also shown that a monoclonal antibody with modifications to the Fc portion of the antibody—making it unable to bind to the Fc receptor CD16—abrogated the ADCC activity [53]. The in vitro growth inhibition assay was performed using two different approaches. The first approach added NK cells at a 3:1 effector (NK) to target (late stage infected RBC) ratio with naïve (USA) serum or hyperimmune serum (pooled Mali adult plasma containing antibodies against both the iRBC surface and merozoites), then let the culture grow. The addition of NK cells increased growth inhibition significantly over hyperimmune plasma alone (averaging 80% vs. 20% respectively), however anti-merozoite antibodies could account for some of the growth inhibition (Fig. 2b) [52]. In addition to this assay, purified late stage infected RBCs were incubated with NK cells at a 3:1 (Effector:Target) ratio for 5 h with USA or Mali plasma, the cells were washed to get rid of any antibodies, and fresh uninfected RBCs were added (Fig. 2c). Growth inhibition was still observed in this assay in the absence of anti-merozoite antibodies.

The contribution of complement was also removed by using plasma free system and purified IgG from the same naïve or immune plasma [52]. In total, these assays implicate NK cell-mediated ADCC as a potential mechanism of acquired immunity that effectively limits Plasmodium growth. Another study also found that in the presence of antibody FasL may be involved as a killing mechanism [45], however a comprehensive assessment of how growth is inhibited is still needed.

Recently, it was demonstrated that adaptive NK cells correlated with protective malaria phenotypes, including decreased parasitaemia and reduced symptoms [35]. Adaptive NK cells are long-lived and have enhanced functionality, but in the past were studied only in the context of human cytomegalovirus (HCMV) and human immunodeficiency virus (HIV) [54, 55]. In the context of Plasmodium infection, adaptive NK cells, which lacked Fc receptor γ chain [55, 56], performed enhanced ADCC function for both degranulation and IFN-γ production in an in vitro PBMC assay (Fig. 2d) [35]. Additionally, subjects that displayed increased frequencies of promyelocytic leukemia zinc finger protein (PLZF) negative adaptive NK cells (which lack a key transcription factor for Fc receptor γ chain expression) in the current season were significantly protected from malaria symptoms the following malaria season [35]. Increased frequencies

Fig. 2 Assays to look at Natural Killer cell function. a Model of the subset of adaptive NK cells that lack Fc receptor γ chain. These cells are particularly skilled at degranulating and producing IFNγ that can help activate the immune response to Plasmodium. b Growth inhibition antibody dependent cellular cytotoxicity assay (Alternative GI-ADCC assay). Synchronized late stage parasite culture is incubated with or without natural killer cells and with or without immune plasma or antibodies. In this assay, the NK cells can kill the infected RBCs but the antibody is still there to allow for growth inhibition via neutralizing activity against merozoites. The resulting inhibition can then be quantified in all groups and compared by looking at parasitaemia. c Growth inhibition antibody dependent cellular cytotoxicity assay (GI-ADCC assay). In this assay late stage purified (>95% pure) infected RBCs are mixed with NK cells with or without immune plasma or antibodies. After 5 h the antibodies are washed out, then uninfected RBCs are added at 100 fold excess. The infected RBCs then rupture and the resulting parasitaemia the next day is used to assess growth inhibition. d Functional analysis of NK cells in mixed PBMCs. PBMCs are incubated at a 1:1 ratio with late stage purified infected RBCs then immune or naive plasma is added. The phenotype and ADCC function is then assessed via surface markers, CD107a as a marker for degranulation and IFNγ by intracellular cytokine staining.
of PLZF negative adaptive NK cells also correlated with reduced parasitaemia and was found to be independent of age [35]. These studies provide the first evidence that one function of protective antibodies may be to “tag” iRBCs for removal by NK cells, leading to reduced parasitaemia and disease symptoms. The frequency of adaptive NK cells in the Malian cohort was 40% of the NK cells and most of the subjects were CMV positive. In non-malaria exposed subjects that are HCMV positive, frequencies of adaptive NK cells are generally not this high (<10%) [55, 56]. It is unclear if HCMV co-infection with malaria further increases adaptive NK cell frequencies. Because mouse NK cells do not perform ADCC well [57, 58], additional studies using human NK cell and humanized mouse systems are needed to further investigate this mechanism. Since it was shown that NK cells killed iRBCs but not merozoites via ADCC [35], the data suggest that surface-expressed iRBC proteins may be good targets for vaccines designed to enhance NK cell function. These data also suggest that promoting the generation of antibodies that bind the CD16 Fc receptor—IgG1 and IgG3 isotypes, which are also complement-fixing antibodies—could benefit parasite clearance.

Non-severe infection - mouse studies

Plasmodium falciparum is restricted to humans, but several Plasmodium strains can infect mice and replicate features of human malaria disease. No one model recapitulates all features of human malaria disease states; however, depending on the strain of parasite and the genetic background of the mouse strain used, a wide range of outcomes can be mechanistically investigated, from parasitaemia to cerebral malaria [59]. Using Plasmodium chabaudi or P. yoelii 17X infection as models of blood stage infection, NK cell frequencies increase [60] as does their production of IFNγ and TNF [40]. Depletion of NK cells with anti-NK1.1 or anti-asialo GM1 Ab resulted in increased mortality, decreased IFNγ, and either slightly increased or no change in parasitaemia levels [22, 61, 62]. These data suggest that NK cells may contribute to control of parasitaemia and/or disease development during P.c. and P.y. infection models in mice, but the approaches used are not specific enough to definitively say that NK cells play a fundamental role in protection.

Severe infection

One severe result of blood stage P. falciparum infection is the development of neurological complications known as cerebral malaria (CM). CM mostly affects children under the age of five in sub-Saharan Africa and can be fatal [63]. Furthermore, over 25% of children that survive CM exhibit long-term cognitive impairment [64, 65]. There are no adjunctive therapies available for CM patients. CM pathogenesis is generally considered to be driven by two distinct processes: sequestration of iRBCs to vascular endothelium and inflammation [66, 67] (Fig. 3). The
sequestration and excessive inflammation lead to the loss of blood brain barrier integrity, ultimately resulting in oedema [68–70]. Infiltration of inflammatory immune cells into the brains of CM patients has not been extensively investigated due to the difficult nature of obtaining samples. A study from three decades ago found that CM patients had significantly reduced NK cell cytotoxicity against K562 cells compared with healthy controls or patients with uncomplicated *P. falciparum* infection [71]. A recent study compared the ability of NK cells purified from patients with uncomplicated malaria to those with severe malaria to control parasite growth in vitro; although the sample size was relatively small, the data suggest that NK cells from patients with severe malaria disease are less capable of controlling *P. falciparum* growth in vitro [51]. This could be due to immune suppression during severe disease or a ‘hyper-immune’ response that ultimately leads to NK cell functional exhaustion [72–74].

In contrast to the relative scarcity of studies on the role of NK cells during human CM, numerous studies have investigated the role of NK cells in the mouse model of CM, known as experimental cerebral malaria (ECM). The ECM mouse model replicates the neurological symptoms, parasite accumulation, and leukocyte infiltration observed in children with CM, including the induction of brain oedema and brain stem death as a predictor of severe disease [75–77]. Numerous studies in both mice and humans have demonstrated that an excessive pro-inflammatory response results in severe immunopathology during malaria [78–80]. IFNγ—which can be secreted in large amounts by NK cells—is a critical mediator of immune-mediated damage during ECM [81, 82]. An initial report using anti-NK1.1 Ab to deplete NK cells suggested that NK cells play no role in ECM [80]. More recent reports using anti-Asialo GM1 Ab suggested that NK cells actively contribute to ECM [83, 84]. This treatment reduced CD8+ T cell priming in the spleen [84] and upregulation of CXCR3 expression [83], a chemokine receptor important for T cell trafficking to the brain. However, treatment with NK1.1 can also deplete NK T cells and innate lymphoid cells (ILCs), whereas anti-Asialo GM1 treatment has been reported to deplete macrophages, basophils, and CD8 T cells among other immune cells. Other studies investigating the natural killer complex (NKC), a genetic region of highly inbred genes encoding several receptors involved in the control of NK cell function, suggest that polymorphisms within the NKC modulate control susceptibility to the development of ECM and the type of immune response (TH1 vs. TH2) that unfolds [85, 86]. These data as a whole suggest that the pro-inflammatory nature of NK cells could contribute to immune-mediated damage during ECM, but development of additional NK cell-specific depletion methods or use of adoptive transfer approaches [9, 87] need to be employed in future studies to definitively identify any pathological role of NK cells during ECM.

In contrast to a potential pathologic role for NK cells, it was recently shown that NK cells can be induced to produce IL-10, which inhibited the pathologic CD8+ T cell response and protected mice from ECM [9]. There is evidence in other disease models, including from other protozoan infections, that NK cells produce IL-10 [11, 12, 88], similar to CD4+ T cells that can produce both IFNγ and IL-10. It was also demonstrated that stimulation of NK cells with IL-15 cytokine complexes induced this “regulatory” NK cell phenotype. Additionally, primary human NK cells produced IL-10 following culture with IL-15 and IL-21 and increase production further with the addition of IL-12 [9]. Further studies are needed to determine if IL-10-producing NK cells contribute to the healthy resolution (or prevention) of inflammation during malaria disease in humans.

Other severe complications of *Plasmodium* infection include placental malaria and severe malaria anaemia (SMA). Placental malaria can result in placental disruption and lead to miscarriages, still birth, low birth rate, and in some cases death of the pregnant woman [89]. It is estimated that 25% of pregnant women in endemic areas are infected with *Plasmodium*, and that this is responsible for 20% of maternal deaths [89]. During this disease, iRBCs express a PFEMP1 protein called Var2CSA that facilitates adherence to chondroitin sulfate A expressed on the placenta [90, 91]. This infiltration and adherence of iRBC to the placenta is believed to be responsible for the observed clinical complications, however the mechanism of disruption is still unclear. Var2CSA is a large and variable gene however its amino acid variation is around 75–85% found in clinical isolates [89]. Women can become immune to placental malaria during successive pregnancies, showing that effective immune protection can be achieved (76, 77). It is unknown if NK cells provide protection against Var2CSA+ infected RBCs through natural cytotoxicity or ADCC. Very few studies have investigated NK cells in the placenta and in the blood at various timepoints [92, 93]. It is known that specialized NK cells in the uterus are necessary for angiogenesis of the placenta that occurs mainly in the first trimester and that NK cells represent 70% of all leukocytes found in the decidua [94]. Furthermore, elevated numbers of IFNγ-producing NK cells and T cells in the placenta is associated with protection [95]. Severe malaria anaemia is characterized by haemoglobin levels less than 5 g/dl, poor erythrocytic output from the bone marrow, and often enlarged spleen [96]. SMA typically occurs in areas that have high exposure rates to *Plasmodium* or are
genetically susceptible to the disease. FcγRIIa is the lone Fc receptor expressed on NK cells that enables ADCC, and polymorphisms in FcγRIIa are associated with SMA [97]. The cell responsible for this association is unknown, but lack of function mutations correlate with poorer outcomes. Whether or not NK cells in these subjects lack effector function has not been explored. In addition, the subset(s) of NK cells associated with placenta malaria or SMA are also unknown. Overall, there is a need for additional studies to indicate if there is a role for NK cells during placental malaria and SMA.

Conclusions
Although increased efforts toward prevention of malaria spread have resulted in significant declines in disease, there is still a need for greater understanding of how an effective immune response against Plasmodium unfolds. Given the mounting evidence of NK cell functional diversity and participation in the immune response to Plasmodium, NK cells represent a new opportunity for improving resistance to malaria—be it through therapeutics or as targets of vaccination approaches [24]. This review summarizes the evidence that NK cells can contribute to the immune response in the clearance of parasites, removal of infected hepatocytes and RBCs through natural cytotoxicity and ADCC, and dampen the adaptive immune response through production of regulatory cytokines. Therefore, NK cells may serve as a critical adjustment point for enhanced immunity to Plasmodium while still preventing immunopathology. However, the number of studies precisely detailing the role of NK cells during different stages of Plasmodium infection and during non-severe and severe forms of disease is sparse. Advances in the understanding of NK cell subsets along with technical improvements should now allow for further consideration of whether NK cells can and should be targeted to improve clinical outcomes during malaria.

Abbreviations
NK: natural killer cell; MHC: major histocompatibility; KIR: killer immunoglobulin-like receptors; NCRs: natural cytotoxicity receptors; DNA-M-1: DNA accessory molecule-1; NKG2D: natural killer cell group 2 member D; ADCC: antibody dependent cellular cytotoxicity; TRAIL: tumour necrosis factor-related apoptosis-inducing ligand; IFNγ: interferon gamma; TNF: tumour necrosis factor; EMP-1: erythrocyte membrane protein-1; HCMV: human cytomegalovirus; HIV: human immunodeficiency virus; PLZF: promyelocytic leukemia zinc finger protein; CM: cerebral malaria; ECM: experimental cerebral malaria; ILCs: innate lymphoid cells; SMA: severe malaria anaemia.

Acknowledgements
The authors are grateful to Michelle Davis and Peter Morawski for assistance with the artistic design of the figures.

Authors’ contributions
All authors contributed to the writing and editing of the manuscript. All authors read and approved the final manuscript.

Funding
The authors thank the University of Minnesota Foundation grant, R01AI143828 (SEH), and F32AI120312 (KSB) for funding support.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Medicine, Hennepin Healthcare Research Institute, Minneapolis, MN 55415, USA. 2 Center for Immunology, Department of Medicine, Division of Infectious Disease and International Medicine, University of Minnesota, Minneapolis, MN 55455, USA. 3 Center for Immunology, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55414, USA.

Received: 7 May 2019   Accepted: 7 September 2019
Published online: 18 September 2019

References
1. Mody CH, Ogboro HO, Xiang RF, Kyel SK, Feehan D, Islam A, et al. Microbial killing by NK cells. J Leukoc Biol. 2019;105:1285–96.
2. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013;31:227–58.
3. Moretta A, Bottino C, Mingani MC, Bassoni R, Moretta L. What is a natural killer cell? Nat Immunol. 2002;3:6–8.
4. Moretta A, Pende D, Locatelli F, Moretta L. Activating and inhibitory killer immunoglobulin-like receptors (KIR) in hapluidentical hematopoietic stem cell transplantation to cure high-risk leukemias. Clin Exp Immunol. 2009;157:325–31.
5. Wallin RP, Screpanti V, Michaelsson J, Grandien A, Ljunggren HG. Regulation of perforin-independent NK cell-mediated cytotoxicity. Eur J Immunol. 2003;33:2727–35.
6. Kayagaki N, Yamauchi N, Nakayama M, Takeda K, Akiba H, Tsutsui H, et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol. 1999;163:1906–13.
7. Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo). 2014;2014:205.96.
8. King T, Lamb T. Interferon-gamma: the Jekyll and Hyde of malaria. PLoS Pathog. 2015;11:e1005118.
9. Burrack KS, Huggins MA, Taras E, Dougherty P, Hendler CM, Yang R, et al. Interleukin-15 complex treatment protects mice from cerebral malaria by inducing interleukin-10-producing natural killer cells. Immunity. 2018;48(760–772):e4.
10. Clark SE, Filak HC, Guthrie BS, Schmidt RL, Jamieson A, Merkel P, et al. Bacterial manipulation of NK cell regulatory activity increases susceptibility to Listeria monocytogenes infection. PLoS Pathog. 2016;12:e1005708.
11. Perona-Wright G, Mohrs K, Szaba FM, Kummer LW, Madan R, Karp CL, et al. Systemic but not local infections elicit immunosuppressive IL-10 production by natural killer cells. Cell Host Microbe. 2009;6:503–12.
12. Tanio ML, Lee S-H, Fragoso MF, Sun H-W, Kanno Y, O’Shea JJ, et al. Proliferation conditions promote intrinsic changes in NK cells for an IL-10 response. Journal of Immunology. 2014;193:354–63.
13. Wolf AS, Sherratt S, Riley EM. NK cells: uncertain allies against malaria. Front Immunol. 2017;8:212.
30. Grivennikov SI, Tumanov AV, Liepinsh DJ, Kruglov AA, Marakusha BI, Nabekura T, Lanier LL. Tracking the fate of antigen-specific versus Narni-Mancinelli E, Chaix J, Fenis A, Kerdiles YM, Yessaad N, Reynders A, Deloron P, Chougnet C, Lepers JP, Tallet S, Coulanges P. Protective value of Artavanis-Tsakonas K, Eleme K, McQueen KL, Cheng NW, Parham P, Ashley EA, Pyae Phyo A, Woodrow CJ. Malaria. Lancet. 2018;391:1608–21. Hart GT, Tran TM, Theorell J, Schlums H, Arora G, Rajagopalan S, et al. 19. Stegmann KA, De Souza JB, Riley EM. IL-18-induced expression of high-affinity IL-2R on murine NK cells is essential for NK-cell IFN-gamma production during murine Plasmodium yoelii infection. Eur J Immunol. 2015;45:3431–40. Horowitz A, Hafalla JC, King E, Lusingu J, Dekker D, Leach A, et al. Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS, S/AS01 malaria vaccine. J Immunol. 2012;188:5054–62. Mpnia M, Maurice NJ, Yajima M, Slichter CK, Miller HW, Dutta M, et al. Controlled human malaria infection leads to long-lasting changes in innate and innate-like lymphocyte populations. J Immunol. 2017;199:107–18. Ng SS, Souza-Fonsceca-Guimarães F, de Rivera FL, Armante FH, Kumar R, Gao Y, et al. Rapid loss of group 1 innate lymphoid cells during blood stage Plasmodium infection. Clin Transl Immunol. 2018;7:e1003. Kazmin D, Nakaya HI, Lee EK, Johnson MJ, van der Most R, van den Bossche HR, Mooney JP, Riley EM, Goodier MR. Vaccinating for natural infection with Plasmodium falciparum. Cell. 2019;175:7466–73. Newman KC, Korbel DS, Hafalla JC, Riley EM. Cross-talk with myeloid accessory cells regulates human natural killer cell interferon-gamma responses to malaria. PLoS Pathog. 2006;2:e118. Mavoungou E, Luty AJ, Kremsner PG. Natural killer (NK) cell-mediated cytolysis of Plasmodium falciparum-infected human red blood cells in vivo. Eur Cytokine Netw. 2003;14:354–42. Mavoungou E, Held J, Mewono L, Kremsner PG. A Duffy binding-like domain is involved in the NKp30-mediated recognition of Plasmodium falciparum-parasitized erythrocytes by natural killer cells. J Infect Dis. 2007;195:1521–31. Bouyou-Akotet MK, Issifou S, Meye JF, Kombla M, Ngou-Milama E, Luty AJ, et al. Depressed natural killer cell cytotoxicity against Plasmodium falciparum-infected erythrocytes during first pregnancies. Clin Infect Dis. 2004;38:342–7. Vaughan AM, Kappe SH, Plass A, Mikolajczak SA. Development of humanized mouse models to study human malaria parasite infection. Future Microbiol. 2012;7:657–65. Chen Q, Amaldoss A, Ye W, Liu M, Dummler S, Kong F, et al. Human natural killer cells control Plasmodium falciparum infection by eliminating infected red blood cells. Proc Natl Acad Sci USA. 2014;111:1479–84. Saito F, Hirayasu K, Satoh T, Wang CW, Lusingu J, Arimori T, et al. Immune evasion of Plasmodium falciparum by RIFIN via inhibitory receptors. Nature. 2017;552:101–5. Ye W, Chew M, Hou J, Lai F, Leopold SJ, Loo HL, et al. Microvesicles from malaria-infected red blood cells activate natural killer cells via MD4/S pathway. PLoS Pathog. 2018;14:e1007298. Arora G, Hart GT, Manzella-Lapeira J, Doritchamou JY, Parham P, Stevenson MM. Natural killer cell cytokine production, not cytotoxicity, contributes to resistance against blood-stage Plasmodium chabaudi AS infection. J Immunol. 1999;163:564–70. Lee J, Zhang T, Hvang I, Kim A, Nitschke L, Kim M, et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity. 2015;42:431–42. Odlillio DL, Ravetch JV. Differential Fc-receptor engagement drives an antitumor vaginal effect. Cell. 2015;161:1035–45. Uchida J, Haraguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network depletes B lymphocytes.
through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199:1659–69.

59. Langhorne J, Quin SJ, Sanni LA. Mouse models of blood-stage malaria infections: immune responses and cytokines involved in protection and pathology. Chem Immunol. 2002;80:204–28.

60. Kim CC, Parikh S, Sun JC, Myrick A, Lanier LL, Rosenthal PJ, et al. Experimental malaria infection triggers early expansion of natural killer cells. Infect Immun. 2008;76:5873–82.

61. Kitaguchi T, Nagoya M, Amano T, Suzuki M, Minami M. Analysis of roles of natural killer cells in defense against Plasmodium chabaudi in mice. Parasitol Res. 1996;82:352–7.

62. Weidanz WP, Lafleur G, Brown A, Burns JM, Gramaglia I, van der Heyde HC. Gammadelta T cells but not NK cells are essential for cell-mediated immunity against Plasmodium chabaudi malaria. Infect Immun. 2010;78:4331–40.

63. WHO. World malaria report 2016. 2016.

64. Carter JA, Mung’ala-Odera V, Neville BGR, Murira G, Mturi N, Musumba C, et al. Persistent neurocognitive impairments associated with severe falciparum malaria in Kenyan children. J Neurosurg Psychiatry. 2005;76:476–81.

65. John CC, Panoskaltsis-Mortari A, Opoka RO, Park GS, Orchard PJ, Jurek AM, et al. Cerebrospinal fluid cytokine levels and cognitive impairment in cerebral malaria. Am J Trop Med Hyg. 2008;78:198–205.

66. Kraemer SM, Smith JD. A family affair: var genes, PfEMP1 binding, and malaria disease. Curr Opin Microbiol. 2006;9:374–80.

67. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498:502–5.

68. Hora R, Kapoor P, Third KK, Mishra PC. Cerebral malaria—clinical manifestations and pathogenesis. Metab Brain Dis. 2016;31:225–37.

69. Storm J, Craig AG. Pathogenesis of cerebral malaria—inflammation and cytoadherence. Front Cell Infect Microbiol. 2014;4:100.

70. Taylor TE, Fu WJ, Carr RA, Whitten RO, Mueller JS, Fosko NG, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med. 2004;10:143–5.

71. Stach JL, Dufrenoy E, Neville BGR, Orchard PJ, Jurek AM, et al. Cerebrospinal fluid cytokine levels and cognitive impairment in cerebral malaria. Am J Trop Med Hyg. 2008;78:198–205.

72. Kraemer SM, Smith JD. A family affair: var genes, PfEMP1 binding, and malaria disease. Curr Opin Microbiol. 2006;9:374–80.

73. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498:502–5.

74. Hora R, Kapoor P, Third KK, Mishra PC. Cerebral malaria—clinical manifestations and pathogenesis. Metab Brain Dis. 2016;31:225–37.

75. Storm J, Craig AG. Pathogenesis of cerebral malaria—inflammation and cytoadherence. Front Cell Infect Microbiol. 2014;4:100.

76. Taylor TE, Fu WJ, Carr RA, Whitten RO, Mueller JS, Fosko NG, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med. 2004;10:143–5.

77. Stach JL, Dufrenoy E, Rohff J, Bach MA. T-cell subpopulations and in vivo influence subpopulations and in vivo influence of cerebral malaria by modulating CD8+ T cells. J Immunol. 2012;189:968–79.

78. Hansen DS, Bernard NJ, Nie CQ, Schofield L. NK cells stimulate recruitment of CCR84+ T cells to the brain during Plasmodium berghei-mediated cerebral malaria. J Immunol. 2007;178:7579–88.

79. Ryg-Corneo V, Nie CQ, Bernard NJ, Lundie RJ, Evans KJ, Crabb BS, et al. NK cells and conventional dendritic cells engage in reciprocal activation for the induction of inflammatory responses during Plasmodium berghei ANKA infection. Immunobiol. 2013;218:263–71.

80. Hansen DS, Evans KJ, D’Oombrain MC, Bernard NJ, Sexton AC, Buckingham L, et al. The natural killer cell complex regulates severe malarial pathogenesis and influences acquired immune responses to Plasmodium berghei ANKA. Infect Immun. 2005;73:2288–97.

81. Hansen DS, Ryg-Corneo V, Ioannidis LI, Chiu CY, Ly A, Nie CQ, et al. The contribution of natural killer cell complex loci to the development of experimental cerebral malaria. PLoS ONE. 2014;9:e93268.

82. Atr MC, Lewis BB, Caballero S, Xiong H, Carter RA, Susac B, et al. Innate immune defenses mediated by two ILC subsets are critical for protection against acute Closidium difficile infection. Cell Host Microbe. 2015;18:27–37.

83. Maroof A, Beatie L, Zubiani S, Svensson M, Stager S, Kaye PM. Posttranscriptional regulation of H10 gene expression allows natural killer cells to express immunoregulatory function. Immunology. 2008;29:295–305.

84. Fried M, Duffy PE. Designing a VAR2CSA-based vaccine to prevent placental malaria. Vaccine. 2015;33:7483–8.

85. Salanti A, Staatske T, Lavstsen T, Jensen AT, Sowa MP, Arnot DE, et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol. 2003;49:179–91.

86. Salanti A, Dahlback M, Turner L, Nielsen MA, Barford L, Magistrado P, et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med. 2004;200:1197–203.

87. Sartelet H, Schleiemacher D, Le-Hesran JY, Graesslin O, Gaillard D, Fe M, et al. Less HLA-G expression in Plasmodium falciparum-infected third trimester placentas is associated with more natural killer cells. Placenta. 2005;26:505–11.

88. Ordi J, Menendez C, Ismail MR, Ventura PJ, Palacin A, Kahigwa E, et al. Placental malaria is associated with cell-mediated inflammatory responses with selective absence of natural killer cells. J Infect Dis. 2003;183:1100–7.

89. Wallace AE, Fraser R, Cartwright JE. Extravillous trophoblast and decidual natural killer cells: a remodelling partnership. Hum Reprod Update. 2012;18:458–71.

90. Othoro C, Moore JM, Wannemuehler KA, Moses S, Lal A, Otoo J, et al. Elevated gamma interferon-producing NK cells, CD45RO memory-like T cells, and CD4 T cells are associated with protection against malaria infection in pregnancy. Infect Immun. 2008;76:1678–85.

91. Perkins DJ, Were T, Davenport GC, Kempiah P, Hittner JB, Ong’echa JM. Severe malarial anemia: innate immunity and pathogenesis. Int J Biol Sci. 2011;7:1427–42.

92. Munde EO, Okeyo WA, Raballah E, Anyona SB, Were T, Ong’echa JM, et al. Perforin-dependent brain-infiltrating cytotoxic CD8+ T lymphocytes mediate experimental cerebral malaria pathogenesis. J Immunol. 2003;170:2221–8.

93. Yażez DM, Manning DD, Cooley AJ, Weidanz WP, van der Heyde HC. Participation of lymphocyte subpopulations in the pathogenesis of experimental murine cerebral malaria. J Immunol. 1996;157:1620–4.

94. Grau GE, Heremans H, Piguet PF, Pointaire P, Lambert PH, Billiau A, et al. Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. Proc Natl Acad Sci USA. 1989;86:5572–4.

95. Villegas-Mendez A, Greig R, Shaw TN, de Souza JB, Gwyer Findlay E, Stumhofer JS, et al. IFN-γ-producing CD4+ T cells promote experimental cerebral malaria by modulating CD8+ T cell accumulation within the brain. J Immunol. 2012;189:968–79.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.